Low-dose-intensity bevacizumab with weekly irinotecan for platinum- and taxanes-resistant epithelial ovarian cancerReport as inadecuate




Low-dose-intensity bevacizumab with weekly irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer - Download this document for free, or read online. Document in PDF available to download.

Cancer Chemotherapy and Pharmacology

, Volume 75, Issue 3, pp 645–651

First Online: 20 January 2015Received: 29 October 2014Accepted: 08 January 2015DOI: 10.1007-s00280-015-2680-4

Cite this article as: Liu, Y., Ren, Z., Xu, S. et al. Cancer Chemother Pharmacol 2015 75: 645. doi:10.1007-s00280-015-2680-4

Abstract

PurposeThe purpose of this study was to evaluate the safety and efficacy of low-dose-intensity bevacizumab and weekly irinotecan as salvage treatment for patients with platinum- and taxanes-resistant advanced epithelial ovarian cancer.

MethodsFifty-two patients with platinum- and taxanes-resistant advanced epithelial ovarian cancer received bevacizumab 5 mg-Kg days 1 and 15; irinotecan 60 mg-m days 1, 8 and 15. The combined therapy was repeated every 28 days, up to six cycles.

ResultsA total of 230 cycles of bevacizumab combined with irinotecan were administrated to 52 patients. Among the 52 patients, 22 patients achieved partial response 42.3 %; 12 patients had stable disease 23.1 % and 18 patients experienced disease progression 34.6 %. The median progression-free survival and the median overall survival were 8.0 months 95 % confidence interval: 6.74–9.26 months and 13.8 months 95 % confidence interval: 11.97–15.63 months, respectively. The most frequent grade 3–4 hematologic toxicities were neutropenia 11.5 % and thrombocytopenia 3.8 %. The non-hematologic toxicities included grade 3 diarrhea 3.8 % and hypertension 3.8 %. Two patients 3.8 % were confirmed with deep vein thrombosis. Febrile neutropenia, symptomatic cardiac dysfunction and gastrointestinal perforation were not observed in this study.

ConclusionsThe combination of low-dose-intensity bevacizumab and weekly irinotecan was an effective and safe regimen for patients with platinum- and taxanes-resistant epithelial ovarian cancer.

KeywordsBevacizumab Irinotecan Platinum-taxanes-resistant Ovarian cancer Ying Liu and Zhonghai Ren have contributed equally to this work.

Download fulltext PDF



Author: Ying Liu - Zhonghai Ren - Shuning Xu - Hua Bai - Ning Ma - Feng Wang

Source: https://link.springer.com/







Related documents